| Autor: |
Syverson EP; Division of Gastroenterology & Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States., Rubinstein E; Division of Gastroenterology & Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States., Lee JJ; Division of Allergy & Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States., McDonald DR; Division of Allergy & Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States., Hait E; Division of Gastroenterology & Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States. |
| Abstrakt: |
Dupilumab has been approved to treat a variety of atopic disorders and was the first US FDA-approved medication for the treatment of eosinophilic esophagitis (EoE), initially approved in May 2022, with expansion in use to patients as young as 1 year of age weighing at least 15 kg in January 2024. It is a fully human monoclonal antibody that inhibits both IL-4 and IL-13 signaling, suppressing TH2-mediated proinflammatory cytokines, chemokines and IgE implicated in EoE pathogenesis. Phase II and III trials in EoE have demonstrated histologic, endoscopic and symptomatic improvement in disease activity with an overall favorable safety profile. This article will review the available clinical trial data and real-world efficacy of dupilumab in EoE. |
